Human dopamine transporter gene: Differential regulation of 18-kb haplotypes

Pharmacogenomics

Volumn 14, Issue 12, 2013, Pages 1481-1494

  Zhao, Ying ^a,b,c   Xiong, Nian ^a,d   Liu, Yang ^a   Zhou, Yanhong ^a   Li, Nuomin ^a,e   Qing, Hong ^e   Lin, Zhicheng ^a  

^a MCLEAN HOSPITAL   (United States)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c XINXIANG MEDICAL UNIVERSITY   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e BEIJING INSTITUTE OF TECHNOLOGY   (China)

Author keywords

DAT; epigenetics; haplotypic activity; promoter; signaling regulation; single copy number reporter vector

Indexed keywords

DOPAMINE TRANSPORTER;

ALLELE; ANIMAL CELL; ARTICLE; CELL TYPE; CONTROLLED STUDY; EMBRYO; GENE; GENE EXPRESSION REGULATION; HAPLOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PHARMACOLOGICAL STIMULATION; PROMOTER REGION; SIGNAL TRANSDUCTION; SLC6A3 GENE; VARIABLE NUMBER OF TANDEM REPEAT;

CELL LINE; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GENE EXPRESSION REGULATION; GENE FREQUENCY; HAPLOTYPES; HUMANS; MINISATELLITE REPEATS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; REGULATORY SEQUENCES, NUCLEIC ACID; SIGNAL TRANSDUCTION;

EID: 84883890926     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.141     Document Type: Article

References (69)

1. Coyle JT, Snyder SH. Antiparkinsonian drugs: Inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action. Science 166(3907), 899-901 (1969
2. Lin Z, Canales JJ, Bjorgvinsson T et al. Monoamine transporters: Vulnerable and vital doorkeepers. Prog. Mol. Biol. Transl. Sci. 98, 1-46 (2011
3. Bannon MJ, Michelhaugh SK, Wang J, Sacchetti P. The human dopamine transporter gene: Gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. Eur. Neuropsychopharmacol. 11(6), 449-455 (2001
4. Berridge KC, Aldridge JW, Houchard KR, Zhuang X. Sequential super-stereotypy of an instinctive fixed action pattern in hyper-dopaminergic mutant mice: A model of obsessive compulsive disorder and Tourette's. BMC Biol. 3, 4 (2005
5. Pecina S, Cagniard B, Berridge KC, Aldridge JW, Zhuang X. Hyperdopaminergic mutant mice have higher "wanting" but not "liking" for sweet rewards. J. Neurosci. 23(28), 9395-9402 (2003
6. Ralph-Williams RJ, Paulus MP, Zhuang X, Hen R, Geyer MA. Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system. Biol. Psychiatry 53(4), 352-359 (2003
7. Salahpour A, Ramsey AJ, Medvedev IO et al. Increased amphetamine-induced hyperactivity and reward in mice overexpressing the dopamine transporter. Proc. Natl Acad. Sci. USA 105(11), 4405-4410 (2008
8. Zhuang X, Oosting RS, Jones SR et al. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc. Natl Acad. Sci. USA 98(4), 1982-1987 (2001
9. Horvath MC, Kovacs GG, Kovari V, Majtenyi K, Hurd YL, Keller E. Heroin abuse is characterized by discrete mesolimbic dopamine and opioid abnormalities and exaggerated nuclear receptor-related 1 transcriptional decline with age. J. Neurosci. 27(49), 13371-13375 (2007
10. Little KY, McLaughlin DP, Zhang L et al. Brain dopamine transporter messenger RNA and binding sites in cocaine users: A postmortem study. Arch. Gen. Psychiatry 55(9), 793-799 (1998
11. Bannon MJ, Pruetz B, Manning-Bog AB et al. Decreased expression of the transcription factor NURR1 in dopamine neurons of cocaine abusers. Proc. Natl Acad. Sci. USA 99(9), 6382-6385 (2002
12. Chen L, Segal DM, Moraes CT, Mash DC. Dopamine transporter mRNA in autopsy studies of chronic cocaine users. Brain Res. Mol. Brain Res. 73(1-2), 181-185 (1999
13. Zhou H, Huang C, Tong J, Hong WC, Liu YJ, Xia XG. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Int. J. Biol. Sci. 7(6), 753-761 (2011
14. Petrie EC, Veith RC, Szot P. Bupropion and desipramine increase dopamine transporter mRNA expression in the ventral tegmental area/substantia nigra of rat brain. Prog. Neuropsychopharmacol. Biol. Psychiatry 22(5), 845-856 (1998
15. Patterson TA, Brot MD, Zavosh A, Schenk JO, Szot P, Figlewicz DP. Food deprivation decreases mRNA and activity of the rat dopamine transporter. Neuroendocrinology 68(1), 11-20 (1998
16. Figlewicz DP, Szot P, Chavez M, Woods SC, Veith RC. Intraventricular insulin increases dopamine transporter mRNA in rat VTA/ substantia nigra. Brain Res. 644(2), 331-334 (1994
17. Dluzen DE, McDermott JL. Neuroprotective role of estrogen upon methamphetamine and related neurotoxins within the nigrostriatal dopaminergic system. Ann. NY Acad. Sci. 914, 112-126 (2000
18. Salkovic-Petrisic M, Lackovic Z. Intracerebroventricular administration of betacytotoxics alters expression of brain monoamine transporter genes. J. Neural. Transm. 110(1), 15-29 (2003
19. Figlewicz DP, Brot MD, McCall AL, Szot P. Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: A molecular study. Brain Res. 736(1-2), 54-60 (1996
20. Shumay E, Chen J, Fowler JS, Volkow ND. Genotype and ancestry modulate brain's DAT availability in healthy humans. PLoS ONE 6(8), e22754 (2011
21. Shumay E, Fowler JS, Volkow ND. Genomic features of the human dopamine transporter gene and its potential epigenetic states: Implications for phenotypic diversity. PLoS ONE 5(6), e11067 (2010
22. Bannon MJ, Whitty CJ. Age-related and regional differences in dopamine transporter mRNA expression in human midbrain. Neurology 48(4), 969-977 (1997
23. Zhou Y, Michelhaugh SK, Schmidt CJ, Liu JS, Bannon MJ, Lin Z. Ventral midbrain correlation between genetic variation and expression of the dopamine transporter gene in cocaine-abusing versus non-abusing subjects. Addict. Biol. doi:10.1111/j.1369- 1600.2011.00391.x (2011) (Epub ahead of print
24. Hill M, Anney RJ, Gill M, Hawi Z. Functional analysis of intron 8 and 3́ UTR variable number of tandem repeats of SLC6A3: Differential activity of intron 8 variants. Pharmacogenomics J. 10(5), 442-447 (2010
25. Miller GM, Madras BK. Polymorphisms in the 3́-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression. Mol. Psychiatry 7(1), 44-55 (2002
26. Zhao Y, Zhou Y, Xiong N, Lin Z. Identification of an intronic cis-acting element in the human dopamine transporter gene. Mol. Biol. Rep. 39(5), 5393-5399 (2012
27. Sacchetti P, Brownschidle LA, Granneman JG, Bannon MJ. Characterization of the 5́-flanking region of the human dopamine transporter gene. Brain Res. Mol. Brain Res. 74(1-2), 167-174 (1999
28. Greenwood TA, Kelsoe Jr. Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene. Genomics 82(5), 511-520 (2003
29. Kelada SN, Costa-Mallen P, Checkoway H et al. Dopamine transporter (SLC6A3) 5́ region haplotypes significantly affect transcriptional activity in vitro but are not associated with Parkinson's disease. Pharmacogenet. Genomics 15(9), 659-668 (2005
30. Bamne MN, Talkowski ME, Chowdari KV, Nimgaonkar VL. Functional analysis of upstream common polymorphisms of the dopamine transporter gene. Schizophr. Bull. 36(5), 977-982 (2010
31. van de Giessen E, de Win MM, Tanck MW, van den Brink W, Baas F, Booij J. Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3. J. Nucl. Med. 50(1), 45-52 (2009
32. VanNess SH, Owens MJ, Kilts CD. The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet. 6, 55 (2005
33. van Dyck CH, Malison RT, Jacobsen LK et al. Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J. Nucl. Med. 46(5), 745-751 (2005
34. Guindalini C, Howard M, Haddley K et al. A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. Proc. Natl Acad. Sci. USA 103(12), 4552-4557 (2006
35. Lin Z, Zhao Y, Chung CY et al. High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life. FASEB J. 24(7), 2191-2200 (2010
36. Uejima H, Lee MP, Cui H, Feinberg AP. Hot-stop PCR: A simple and general assay for linear quantitation of allele ratios. Nat. Genet. 25(4), 375-376 (2000
37. Ekins S, Nikolsky Y, Bugrim A, Kirillov E, Nikolskaya T. Pathway mapping tools for analysis of high content data. Methods Mol. Biol. 356, 319-350 (2007
38. Chung CY, Seo H, Sonntag KC, Brooks A, Lin L, Isacson O. Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum. Mol. Genet. 14(13), 1709-1725 (2005
39. Jones SR, Gainetdinov RR, Hu XT et al. Loss of autoreceptor functions in mice lacking the dopamine transporter. Nat. Neurosci. 2(7), 649-655 (1999
40. Huang SY, Chen HK, Ma KH et al. Association of promoter variants of human dopamine transporter gene with schizophrenia in Han Chinese. Schizophr. Res. 116(1), 68-74 (2010
41. Genro JP, Polanczyk GV, Zeni C et al. A common haplotype at the dopamine transporter gene 5́ region is associated with attention-deficit/ hyperactivity disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B(8), 1568-1575 (2008
42. Xu X, Mill J, Sun B et al. Association study of promoter polymorphisms at the dopamine transporter gene in attention deficit hyperactivity disorder. BMC Psychiatry 9, 3 (2009
43. Wang J, Bannon MJ. Sp1 and Sp3 activate transcription of the human dopamine transporter gene. J. Neurochem. 93(2), 474-482 (2005
44. Son JH, Chun HS, Joh TH, Cho S, Conti B, Lee JW. Neuroprotection and neuronal differentiation studies using substantia nigra dopaminergic cells derived from transgenic mouse embryos. J. Neurosci. 19(1), 10-20 (1999
45. Fishman-Jacob T, Reznichenko L, Youdim MB, Mandel SA. A sporadic Parkinson disease model via silencing of the ubiquitin-proteasome/E3 ligase component SKP1A. J. Biol. Chem. 284(47), 32835-32845 (2009
46. Wang J, Michelhaugh SK, Bannon MJ. Valproate robustly increases Sp transcription factor-mediated expression of the dopamine transporter gene within dopamine cells. Eur. J. Neurosci. 25(7), 1982-1986 (2007
47. Shizuya H, Birren B, Kim UJ et al. Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using an F-factor-based vector. Proc. Natl Acad. Sci. USA 89(18), 8794-8797 (1992
48. Bartlett CW, Flax JF, Fermano Z et al. Gene x gene interaction in shared etiology of autism and specific language impairment. Biol. Psychiatry 72(8), 692-699 (2012
49. Yacubian J, Sommer T, Schroeder K et al. Gene-gene interaction associated with neural reward sensitivity. Proc. Natl Acad. Sci. USA 104(19), 8125-8130 (2007
50. Ma L, Brautbar A, Boerwinkle E, Sing CF, Clark AG, Keinan A. Knowledge-driven analysis identifies a gene-gene interaction affecting high-density lipoprotein cholesterol levels in multi-ethnic populations. PLoS Genet. 8(5), e1002714 (2012
51. Okada Y, Kubo M, Ohmiya H et al. Common variants at CDKAL1 and KLF9 are associated with body mass index in east Asian populations. Nat. Genet. 44(3), 302-306 (2012
52. Frieling H, Romer KD, Scholz S et al. Epigenetic dysregulation of dopaminergic genes in eating disorders. Int. J. Eat. Disord. 43(7), 577-583 (2010
53. Vucetic Z, Carlin JL, Totoki K, Reyes TM. Epigenetic dysregulation of the dopamine system in diet-induced obesity. J. Neurochem. 120(6), 891-898 (2012
54. Fuke S, Sasagawa N, Ishiura S. Identification and characterization of the Hesr1/Hey1 as a candidate trans-acting factor on gene expression through the 3́ non-coding polymorphic region of the human dopamine transporter (DAT1) gene. J. Biochem. 137(2), 205-216 (2005
55. Fuke S, Minami N, Kokubo H et al. Hesr1 knockout mice exhibit behavioral alterations through the dopaminergic nervous system. J. Neurosci. Res. 84(7), 1555-1563 (2006
56. Yang B, Chan RC, Jing J, Li T, Sham P, Chen RY. A meta-analysis of association studies between the 10-repeat allele of a VNTR polymorphism in the 3́-UTR of dopamine transporter gene and attention deficit hyperactivity disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B(4), 541-550 (2007
57. Joober R, Grizenko N, Sengupta S et al. Dopamine transporter 3́-UTR VNTR genotype and ADHD: A pharmaco-behavioural genetic study with methylphenidate. Neuropsychopharmacology 32(6), 1370-1376 (2007
58. Hawi Z, Kent L, Hill M et al. ADHD and DAT1: Further evidence of paternal over-transmission of risk alleles and haplotype. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B(1), 97-102 (2010
59. Sachs GS, Ice KS, Chappell PB et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: A randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 72(10), 1413-1422 (2011
60. Li SC, Aggarwal SK. Estimation of resource utilisation difference between lithium and valproate treatment groups from the VALID study. J. Med. Econ. 14(3), 350-356 (2011
61. Casey DE, Daniel DG, Tamminga C et al. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacology 34(5), 1330-1338 (2009
62. Meltzer HY, Bonaccorso S, Bobo WV, Chen Y, Jayathilake K. A 12 month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: Influence of valproic acid augmentation. J. Clin. Psychiatry 72(12), 1602-1610 (2011
63. Leon AC, Solomon DA, Li C et al. Antiepileptic drugs for bipolar disorder and the risk of suicidal behavior: A 30 year observational study. Am. J. Psychiatry 169(3), 285-291 (2012
64. Vieta E, Owen R, Baudelet C, McQuade RD, Sanchez R, Marcus RN. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: A 46-week, open-label extension following a 6-week double-blind study. Curr. Med. Res. Opin. 26(6), 1485-1496 (2010
65. Glick ID, Bosch J, Casey DE. A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive. J. Clin. Psychopharmacol. 29(3), 267-271 (2009
66. Houston JP, Ahl J, Meyers AL, Kaiser CJ, Tohen M, Baldessarini RJ. Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex. J. Clin. Psychiatry 67(8), 1246-1252 (2006
67. Sokolski KN, Denson TF. Adjunctive quetiapine in bipolar patients partially responsive to lithium or valproate. Prog. Neuropsychopharmacol. Biol. Psychiatry 27(5), 863-866 (2003
68. Tohen M, Chengappa KN, Suppes T et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch. Gen. Psychiatry 59(1), 62-69 (2002
69. Geiger H, Pawar SA, Kerschen EJ et al. Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. Nat. Med. 18(7), 1123-1129 (2012